The launch of "Comparison of the Efficacy of 24 Brands of Rapid Antigen Test Reagents", organized by the Hong Kong Biomedical Innotech Association (HKBMIA), has drawn to a close recently. Many experts in biological research and testing technology from Hong Kong participated in this efficacy comparison. Firstly, these experts aimed to analyze the test agents based on publicly available information, i.e. to check whether they belonged to an authoritative approved list, e.g. whether they belonged to the HKSAR government approved, NMPA approved, FDA approved, CE certificate. Secondly, the independent German PEI study results and the manufacturer's clinical performance data were consulted. In addition to this, the experts also compared the 24 reagents included in the selection by combining many indicators such as sensitivity, specificity, stability and user-friendliness. The comparison results showed that the Rapid Antigen detection reagents from our company - Getein were rated in the top 4 of the overall list and the top 9 of the comparative study of the tests.

During the COVID-19 pandemic, the safety and security of individuals is a top priority in the current outbreak. Getein has been continuously expanding and updating the range of COVID-19 reagents and enhancing its research and development capabilities to protect people's health. As one of the leaders in the field of in vitro diagnostics in China, Getein not only provides innovative testing products and quality services to medical institutions and patients but also shows the public the rising role of Chinese enterprises in the fight against the pandemic with its hardcore, high efficiency, innovation and commitment. It has also shown the world the tremendous power of Chinese companies in responding to major public health events.

The Hong Kong SAR Government Department of Health Center for Health Protection announced on the afternoon of March 16 - as midnight of that day, 14,454 new patients of novel coronavirus pneumonia confirmed by Nucleic Acid Test were diagnosed in Hong Kong; 14,818 new cases were added to the Rapid Antigen Test positive reporting platform; a total of 29,272 new cases were confirmed throughout the day. From this data, it is easy to see that the Rapid Antigen Test accounted for almost half of the confirmed cases. In the early fight against the pandemic in Hong Kong, there was often a shortage of test kits and insufficient test capacity. The fifth wave of the outbreak in Hong Kong is raging and has plagued many people, and Getein is no exception. With 20 years of experience in the industry, Getein quickly integrated resources and increased production capacity and sent large quantities of antigen self-testing supplies to Hong Kong urgently to protect our compatriots in Hong Kong and bring great convenience to the detection and treatment of novel coronavirus pneumonia.

The product that Getein were evaluated in Hong Kong is the One Step Test for SARS-CoV-2 Antigen (Colloidal Gold), which is very easy and fast to operate. No testing equipment is required. Individuals could perform the test by collecting nasal swab samples themselves. The sampling process is simple and comfortable, and the test results can be obtained in just 10-15 minutes. The convenient operation allows this test to be suitable in many scenarios such as home, workplace, school, etc.

Hitherto, Getein's One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) (for self-test) has received CE certification and has been listed in the EU common list. Besides, the test kit has been validated and approved by Thailand FDA, Malaysia MDA, the Philippines FDA and the UK CTDA. In addition, Getein One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) has also passed the PEI evaluation and the phase 3a validation of British DHSC. Moreover, the product has been approved by several European countries, including the ANSM COVID-19 antigen white-list and the Italian Ministry of Health white-list, etc. It has been widely accepted in the global market.

This recognition from the HKBMIA will encourage and monitor the future development and production of Getein. Also, we will continue to improve and optimize the quality of our testing reagents. Getein will not forget our original intention and continue to move forward to achieve self-monitoring and enhance the quality of our products to help the industry progress. Getein will take practical action to support the pandemic's frontline warriors and be their strong backing.